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Abstract.9
Background: Chronic obstructive pulmonary disease (COPD) is a major disease burden which accounts for 5% of all deaths
globally, with most of those (>90%) occurring in lower to middle income countries (LMIC). It is also emerging as an important
modifiable dementia risk factor.
10
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Objective: To address the knowledge gap surrounding the nature of the associations between COPD, dementia, and mortality,
and the geographical variation of those associations in LMIC.
13
14
Methods: Data from the 10/66 study surveying 15,394 participants (mean age 74 years, 62% female) across 8 countries
was used to estimate the prevalence of self-reported COPD and its association with incident dementia and premature death.
Proportional sub-hazards models using a cumulative incidence function were applied to identify the probability of incident
dementia onset given the risk of premature death, with estimates pooled across countries via random effect meta-analysis.
15
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18
Results: Over the 3-year follow-up, almost 10% of participants developed dementia and 14% were deceased. COPD was not
significantly associated with dementia incidence except in Cuba. However, fully adjusted models indicated that individuals
with COPD were at a 28% increased risk of premature death, a trend present across most countries when analyzed individually.
19
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21
Conclusion: The link between COPD and dementia is currently somewhat different and weaker in LMIC than in developed
countries. This may be because premature death in the populations studied mask the development of clinical dementia. Given
the global trend toward increased life expectancy, it is critical that the disease burden associated with COPD be addressed
without delay if a further rise in dementia prevalence associated with COPD is to be avoided in LMIC.
22
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INTRODUCTION28
The prevalence of dementia is projected to increase29
substantially worldwide in the coming decades from30
1Statistical analysis.
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46.8 million in 2015 to 131.5 million in 2050 [1]. 31
While currently it is estimated that 58% of people 32
with dementia live in low to middle-income coun- 33
tries (LMIC), this proportion is forecast to increase to 34
68% by mid-century due to the different demographic 35
profiles of these regions [1]. 36
In the absence of disease modifying treatment 37
availability and/or affordability, this increase in 38
dementia prevalence will lead to dramatic increase 39
in disease burden in countries that can least afford 40
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it unless non-pharmacological interventions can be41
developed to delay the onset of dementia. It is there-42
fore essential to better understand the associations43
between risk factors and dementia risk in LMICs.44
One emerging risk factor particularly relevant45
to LMIC is chronic obstructive pulmonary disease46
(COPD). COPD is a major disease burden which47
accounts for 5% of all deaths globally, with most of48
those (>90%) occurring in LMIC (WHO). Its preva-49
lence is about 12% worldwide with higher rates in50
the Americas (∼15%) and lower rates in South East51
Asia (10%) [2]. COPD is characterized by persistent52
lung airflow limitation, typically progressive, which53
is associated with chronic inflammation of the air-54
ways and lungs [3]. Tobacco smoke is the main cause55
of COPD worldwide. Both in human and animal mod-56
els, tobacco smoke leads to an inflammatory response57
within minutes or hours of inhalation [4, 5]. Sustained58
use of tobacco leads to chronic lung inflammation59
which contributes to lung tissue damage, impairs its60
repair, and leads to emphysema, increased risk of61
infection, and increased production of mucus [6].62
Excess mucus accumulates in smaller airways and63
alveoli, and obstructs large airways thus decreas-64
ing airflow and total lung capacity [7] and leads to65
increasing breathlessness, coughing, and expectora-66
tion [8].67
The systemic effects of COPD are not completely68
understood, but it is thought to increase chronic69
peripheral inflammation which can contribute to vas-70
cular pathology, including in the brain, increased71
apoptosis, accelerated tissue senescence, and neu-72
rodegeneration [9–11]. COPD is also thought to73
impair cerebral perfusion and promote hypoxia thus74
further contributing to neurodegeneration and cog-75
nitive impairment [12]. While smoking is the main76
cause of COPD, other risk factors including air pollu-77
tion, childhood disadvantage, professional exposure78
to chemicals, lifestyle (obesity, exercise, diet), and79
genetics are also thought to contribute to the devel-80
opment of the disease [13].81
In high income countries, COPD is associated with82
an almost two-fold increased risk of minor and major83
neurocognitive disorders [14, 15] and a two-fold84
increased risk of premature death [16]. However, lit-85
tle is known about the association between COPD and86
dementia, and its complex relationship with poverty87
and lower life expectancy, in LMIC. Recent evi-88
dence suggests that while smoking is also strongly89
associated with COPD in LMIC, the main mortal-90
ity risk in these countries may be more strongly91
linked to poverty and environmental factors than92
to smoking [17]. A possible implication of these 93
findings is that the association between COPD and 94
dementia risk may be different in LMIC compared 95
to high income countries. In addition, the lower life 96
expectancy prevalent in LMIC is likely to mask the 97
late-life adverse impact of COPD and particularly 98
with respect to the development of clinical dementia. 99
It is therefore critical to consider the contribution of 100
COPD-related mortality when interpreting dementia 101
risk in LMIC. 102
Few normative datasets are available to query com- 103
plex interactions between COPD, dementia risk, and 104
mortality in LMIC while contrasting regional differ- 105
ences. The 10/66 study [18] is the first large-scale 106
study focused on investigating dementia prevalence 107
and risk factors in large LMIC populations using a 108
consistent and comparable methodology. Although 109
the main focus of the study was around the epidemi- 110
ology of dementia, the scope of the research is much 111
broader, including other health domains (chronic dis- 112
eases, disability, frailty, poly-morbidity) and social 113
aspects of aging. 114
Leveraging against this rich resource, the aims 115
of this study were to investigate 1) the prevalence 116
of COPD and 2) the prospective risk of demen- 117
tia and mortality attributable to COPD in older 118
community-living individuals living in 8 LMIC 119
(Cuba, Dominican Republic, Peru, Venezuela, Mex- 120
ico, China, India, Puerto Rico) using data from the 121
10/66 study. 122
METHODS 123
Study population 124
Population-based surveys were carried across 125
eleven catchment areas across seven low- and middle- 126
income countries, selected on the basis of a paucity 127
of information about dementia in those regions 128
(Dominican Republic, Peru, Venezuela, Mexico, 129
China, India, and Puerto Rico). This was part of 130
the baseline phase of the 10/66 Dementia Research 131
project, described in depth elsewhere [19]. Briefly, 132
urban and rural catchment areas were identified such 133
that the sample included both high urban density 134
and low-population agrarian lifestyles. Participants 135
were identified by systematic door-knocking of every 136
household within these precisely defined and mapped 137
catchment areas. Those aged 65 years and over were 138
eligible for participation. Initial baseline data collec- 139
tion took place between 2003 and 2005. Follow-up 140
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Table 1
Sample selection and size, by country
Site Baseline Lost Follow-up
Int. MC Dementia N (% of baseline Int. Deceased Dementia Censored
(% of baseline N) (% of follow-up (% of follow-up (% of follow-up
int.) int.) int.) int.)
Cuba 2944 13 313 (10.63%) 2618 327 (12.4%) 2291 433 (18.9%) 182 (7.94%) 1676 (73.15%)
Dominican Rep. 2011 3 235 (11.68%) 1773 335 (18.89%) 1438 323 (22.46%) 165 (11.47%) 950 (66.07%)
Peru 1933 9 162 (8.38%) 1762 444 (25.19%) 1318 101 (7.66%) 77 (5.84%) 1140 (86.50%)
Venezuela 1965 61 109 (5.55%) 1795 467 (26.02%) 1328 139 (10.47%) 151 (11.37%) 1038 (78.16%)
Mexico 2003 0 171 (8.53%) 1832 311 (16.97%) 1521 157 (10.32%) 130 (8.55%) 1234 (81.13%)
China 2162 0 137 (6.34%) 2025 193 (9.53%) 1832 380 (20.74%) 207 (11.29%) 1245 (67.97%)
India 2004 3 181 (9.03%) 1820 – – – – –
Puerto Rico 2009 7 233 (11.59%) 1769 399 (22.56%) 1370 170 (12.40%) 153 (11.17%) 1047 (76.43%)
Total 17031 96 1541 (9.05%) 15394 2476 (16.08%) 11098 1703 (15.34%) 1065 (9.60%) 8330 (75.06%)
Int., number of participants interviewed; MC, missing COPD data; N, total number of participants available at baseline; Lost, number of
participants lost between baseline and follow-up. India is excluded from follow-up due to lack of robust dementia information. Urban and
rural populations are pooled to maximize sample size for subsequent analyses.
took place approximately three years later, between141
2007 and 2010. Based on the estimated sample size142
required to detect the typical dementia prevalence in143
this age group (4.5%), a target of ∼1000 individuals144
per catchment was set. Response rates ranged from145
74% to 98%. Of an initial 17,031 participants, 1,637146
participants were excluded due to missing COPD data147
or existent dementia diagnoses at baseline (Table 1),148
resulting in a sample size of 15,394. The ethical149
aspects of this research were approved by ethics com-150
mittees local to data collection, and the Institute of151
Psychiatry, King’s College London. Written consent152
was obtained from participants or next of kin if the153
individual lacked capacity. Oral consent, witnessed in154
writing by someone literate, was taken from illiterate155
participants.156
Interviews and key measures157
The baseline assessment took 60–180 minutes, and158
included self and informant report questionnaires,159
structured clinical interviews, and physical examina-160
tion on a range of social, physical, and psychological161
health topics. This was conducted in the native lan-162
guage of each catchment area. COPD was ascertained163
via self-report at baseline as in Sousa et al. [20],164
via the question “Do you usually cough up phlegm165
from your chest first thing in the morning?”. This166
is based on findings that show that 75% of individ-167
uals suffering from COPD report chronic coughing168
and sputum production [21]. In contrast, only 12% of169
adults report chronic cough in the general population170
[22], and those who do are at a three-fold increased171
risk of developing COPD (i.e., 75% of those with172
consistent cough/sputum will develop COPD) over 173
10 years [23]. Dementia was assessed using cross- 174
culturally specific criteria developed for the 10/66 175
program [24]. A diagnosis was established based 176
on a cognitive tests battery, clinical interviews, and 177
informant reports (including Community Screen- 178
ing Instrument for Dementia; the CERAD 10 word 179
list learning and animal naming tests; the Geriatric 180
Mental State Examination, and the History and Aeti- 181
ology Schedule – Dementia Diagnosis and Subtype), 182
and was validated against local clinicians DSM-IV 183
diagnoses (see Prince et al. [25] for more infor- 184
mation). The same method was applied at baseline 185
and follow-up, and death information obtained from 186
key informants to determine vital status, date of 187
death of those deceased and a verbal autopsy on 188
those deceased. As described in Ferri et al. [26], 189
this consisted of the World Health Organization’s 190
“Standard Verbal Autopsy Questionnaire 3: Death 191
of a Person Aged 15 Years and Above”, a formal 192
interview with individuals familiar with the deceased 193
persons, as records are typically unavailable). Indi- 194
viduals who were thought to have died with dementia 195
(via verbal autopsy) were coded as incident demen- 196
tia, rather than death. Covariate information was 197
obtained at baseline. Sex, age, education, smok- 198
ing status (non-smoker, ex-smoker, current smoker), 199
physical activity (very, fairly, not very, or not at 200
all physically active), diabetes (participant told by 201
a doctor), stroke (participant told by a doctor), haz- 202
ardous alcohol consumption (more than 14 units per 203
week for women and more than 21 for men), and 204
depression (any major depressive episode accord- 205
ing to F32 depressive episode, specified as mild, 206
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moderate or severe according to ICD-10 criteria207
[27] based on a computerized algorithm, AGECAT,208
applied to the Geriatric Mental State Examination209
which was administered to all participants [28])210
were obtained by self-report. Hypertension was211
obtained by self-report, or meeting International212
Society for Hypertension criteria [29] during physical213
examination.214
Statistical analyses215
The analysis method was consistent with other216
studies in the 10/66 dataset [19]. Analyses were217
carried out on STATA (version 14) and R (ver-218
sion 3.2.0) for Windows, following procedures used219
previously with 10/66 data [30]. The impact of inclu-220
sion/exclusion criterion and attrition was evaluated221
with t and chi-square tests. The association between222
COPD prevalence and covariates (sex, age, educa-223
tion, smoking status, physical activity, hypertension,224
diabetes, stroke, hazardous alcohol use, and depres-225
sion) were investigated via mutually-adjusted preva-226
lence ratios from Poisson regression. The prevalence227
of COPD at baseline was adjusted for compositional228
effects of age (grouped into 65–69, 70–74, and 75–79,229
and 80+ rather than specified as a continuous vari-230
able to make it more interpretable particularly given231
the substantial variation in life expectancy across232
countries), sex, and education. After accounting for233
household clusters using the sandwich estimator of234
variance (vce (robust) command in STATA), these235
adjusted prevalence proportions are reported with236
robust 95% confidence intervals.237
The association between COPD and dementia inci-238
dence and COPD and mortality was modelled using239
Fine and Gray proportional subhazards model [31], a240
cumulative incidence function that disentangles prob-241
ability of dementia onset given the risk of competing242
events (e.g., death before dementia onset). Urban and243
rural populations were pooled to maximize sample244
size. Although sensitivity analyses contrasting urban245
and rural populations were originally planned, pilot246
analyses showed that estimates could not be reliably247
computed due to unstable/non-converging models248
possibly linked to differences in attrition rates in rural249
and urban settings. Both uncontrolled (no covariates)250
and fully controlled (adjusting for sex, age, educa-251
tion, smoking status, physical activity, hypertension,252
diabetes, and stroke) models were fitted. Participants253
were nested by household in all models.254
All analyses were carried out for each coun-255
try separately, and then pooled in a fixed-effects256
meta-analysis [32]. Heterogeneity was examined via 257
Higgin’s I2. Significance was inferred by robust con- 258
fidence intervals, with alpha set at 0.05. 259
RESULTS 260
Sample selection and baseline characteristics 261
From 15,394 dementia-free participants with 262
COPD data available at baseline, 2,476 were lost 263
to follow-up, including all of the data from India 264
(there was no follow-up in India), resulting in a final 265
sample of 11,098 (Table 1). Excluded and included 266
participants did not significantly differ in terms of 267
smoking status, hypertension, or diabetes. Excluded 268
participants were significantly older (t = 31.12, 95% 269
[6.98, 6.15]; mean age of 80.16 versus 73.59) more 270
likely to be female (χ2 = 26.36, p < 0.01; 69% ver- 271
sus 62% female), have a higher level of education 272
(χ2 = 238, p < 0.01; 93% versus 89% having com- 273
pleted secondary education), and be less physically 274
active (χ2 = 1749, p < 0.01; 4% versus 95% being 275
very physically ac ive). COPD prevalence for the 276
included 11,098 participants is summarized by site 277
Fig. 1. COPD Prevalence by site. Figures in white boxed refer to
absolute number of individuals with COPD per site, while bars
refer to percentage of total sample at each site with COPD. Note
y axis is truncated at 7%, the zoomed-in view here is to allow
clearer comparisons between sites. Prevalence is unadjusted. See
Supplementary Table 1 for descriptive statistics for covariates, both
overall and grouped by with and without COPD.
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Table 2
Descriptive statistics for sample at baseline, by country, comparing those with and without COPD
Site COPD Sex Age Education Smoking status Physical Activity Hypertension T2DM Stroke Hazardous Depression
status (female) None Some, did not Completed Completed Tertiary Ex Current Fairly often Very often (yes) (yes) (yes) Alcohol (yes) (yes)
complete primary secondary
Cuba Yes 50∗ (43) 75.06 (7.06) 4 (5.33) 33 (5.05) 36 (3.68) 30 (4.13) 12 (2.41) 32∗ (4.23) 47 (8.36) 52 (4.15) 21 (2.91) 82 (3.79) 13∗ (2.39) 12 (5.26) 8 (7.69) 9 (6.25)
No 1855∗ (66) 75.06 (6.94) 71 (94.67) 621 (94.95) 942 (96.32) 696 (95.87) 485 (97.59) 725∗ (95.77) 515 (91.64) 1201 (95.85) 700 (97.09) 2082 (96.21) 530∗ (97.61) 216 (94.74) 96 (92.31) 135 (93.75)
DR Yes 82 (60) 75.23 (7.50) 33 (8.42) 67 (6.56) 20 (5.41) 9 (6.67) 5 (6.85) 46∗ (6.47) 29 (11.65) 22∗ (3.99) 43 (6.05) 97 (6.32) 20 (7.14) 14 (8.00) 18 (7.69) 37∗ (13.31)
No 1243 (66) 75.64 (7.68) 359 (91.58) 954 (93.44) 350 (94.59) 126 (93.33) 68 (93.15) 665∗ (93.53) 220 (88.35) 530∗ (96.01) 668 (93.95) 1439 (93.68) 260 (92.86) 161 (92.00) 216 (92.31) 241∗ (86.69)
Peru Yes 60 (65) 74.76 (7.35) 6 (4.96) 6 (2.60) 35 (4.83) 31 (6.02) 14 (4.38) 20∗ (7.81) 6 (8.82) 36 (4.69) 28 (4.96) 52 (5.43) 7 (4.05) 10 (7.58) 0 (0) 7 (6.86)
No 1117 (61) 75.25 (7.28) 115 (95.04) 225 (97.40) 690 (95.17) 484 (93.98) 95.63 (95.63) 236∗ (92.19) 62 (91.18) 731 (95.31) 537 (95.04) 906 (94.57) 166 (95.95) 122 (92.42) 8 (100) 95 (93.14)
Venezuela Yes 76 (59) 72.18∗ (6.64) 17 (11.11) 30 (6.82) 60 (6.31) 14 (5.30) 8 (8.99) 50∗ (8.10) 25 (11.85) 48∗ (5.47) 10 (2.93) 94 (6.76) 25 (8.12) 18∗ (13.64) 0 (0) 11 (11.58)
No 1130 (50) 75.41∗ (8.40) 136 (88.89) 410 (93.18) 891 (93.69) 250 (94.70) 81 (91.01) 567∗ (91.90) 186 (88.15) 829∗ (94.53) 331 (97.07) 1296 (93.24) 283 (91.88) 114∗ (86.36) 17 (100) 84 (88.42)
Mexico Yes 87 (62) 74.26 (6.61) 42 (7.58) 62 (7.18) 21 (5.98) 8 (6.45) 65.56) 38 (8.52) 6 (3.33) 56 (6.52) 24 (5.56) 87 (6.91) 35 (8.05) 10 (7.09) 4∗ (20.00) 8 (8.70)
No 1181 (63) 74.76 (7.19) 512 (92.42) 802 (92.82) 330 (94.02) 116 (93.55) 102 (94.44) 408 (91.48) 174 (96.67) 803 (93.48) 408 (94.44) 1172 (93.09) 400 (91.95) 131 (92.91) 16∗ (80.00) 84 (91.30)
China Yes 21∗ (40) 73.17∗ (6.11) 16 (1.97) 12 (4.49) 13 (2.31) 10 (2.63) 1 (0.70) 11∗ (8.94) 15 (3.01) 5∗ (0.69) 7 (2.08) 36 (2.76) 9 (4.41) 8∗ (6.30) 1 (1.69) 1 (10.00)
No 1196∗ (57) 74.82∗ (6.60) 795 (98.03) 255 (95.51) 549 (97.69) 370 (97.37) 141 (99.30) 112∗ (91.06) 483 (96.99) 722∗ (99.31) 330 (97.92) 1268 (97.24) 195 (95.59) 119∗ (93.70) 58 (98.31) 9 (90.00)
India Yes 35∗ (37) 71.93 (5.94) 54 (4.96) 28 (6.53) 9 (2.74) 3 (2.68) 0 (0) 7∗ (5.47) 46 (6.88) 63∗ (4.9) 7 (1.74) 36∗ (3.19) 7 (3.76) 1 (3.23) 1 (20.00) 16∗ (9.70)
No 1080∗ (57) 72.69 (6.84) 1034 (95.04) 401 (93.47) 319 (97.26) 109 (97.32) 43 (100) 121∗ (94.53) 623 (93.12) 1223∗ (95.10) 395 (98.26) 1094∗ (96.81) 179 (96.24) 30 (96.77) 4 (80.00) 149∗ (90.30)
Puerto Rico Yes 42 (74) 76.36 (7.42) 6 (8.33) 10 (2.57) 10 (2.41) 19 (2.66) 12 (2.93) 15 (3.38) 4 (3.85) 14∗ (1.50) 2 (0.58) 53∗ (3.53) 22 (3.43) 10∗ (5.95) 1 (3.57) 4∗ (8.70)
No 1305 (67) 75.93 (7.08) 66 (91.67) 379 (97.43) 405 (97.50) 694 (97.34) 398 (97.07) 429 (96.62) 100 (96.15) 922∗ (98.50) 340 (99.42) 1448∗ (96.47) 620 (96.57) 158∗ (94.05) 27 (96.43) 42∗ (91.30)
T2DM, type 2 diabetes mellitus. Values are mean for continuous variables, and counts for categorical variables. Values in brackets () are percentages for categorical variables and SD for continuous
variables. ∗indicates a significant difference between individuals with or without COPD revealed by t (for continuous) or χ2 (for categorical) tests (see Supplementary Table 1 for more information).
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Table 3
Meta-analyzed and mutually adjusted prevalence ratios (PR) estimates [95% confidence intervals] from a Poisson regression for the independent effects of covariates on COPD prevalence at
baseline
Site Sex Age Education Smoking status Physical Activity Hypertension T2DM Stroke Depression Hazardous Coefficient
(female) Ex Current Fairly often Very often (yes) (yes) (yes) (yes) Alcohol (yes)
Cuba 1.82 1 0.82 1.48 2.82 0.91 0.64 0.9 0.65 1.17 1.85 1.38 63.54,
(1.22, 2.72)∗ (0.97, 1.03) (0.69, 1) (0.90, 2.46) (1.76, 4.52)∗ (0.61, 1.34) (0.37, 1.09) (0.61, 1.32) (0.37, 1.15) (0.66, 2.07) (0.95, 3.61) (0.70, 2.70) p < 0.01
DR 1.29 0.99 0.93 1.10 1.99 0.48 0.73 0.78 1.08 0.97 1.93 0.96 48.80,
(0.89, 1.87) (0.97, 1.01) (0.77, 1.13) (0.75, 1.63) (1.28, 3.10)∗ (0.30, 0.78)∗ (0.48, 1.10) (0.54, 1.13) (0.67, 1.75) (0.56, 1.70) (1.28, 2.89)∗ (0.57, 1.62) p < 0.01
Peru 0.68 1 1.07 2.18 2.36 1.08 1.24 1.14 0.79 1.46 1.37 – 927.69,
(0.44, 1.05) (0.98, 1.04) (0.88, 1.29) (1.28, 3.69)∗ (1.79, 2.09)∗ (0.65, 1.79) (0.73, 2.09) (0.73, 1.79) (0.38, 1.67) (0.76, 2.82) (0.63,2.94) p < 0.01
Venezuela 1.65 1.05 1.13 1.37 3.26 0.93 0.62 1.17 1.73 1.04 2.10 – 1570.20,
(0.98, 2.78) (1.02, 1.09)∗ (0.78, 2.4) (0.78, 2.41) (1.72, 6.18)∗ (0.52, 1.66) (0.25, 1.53) (0.54, 2.53) (0.95, 3.15) (0.422, 2.54) (0.87,5.10) p = 0.07
Mexico 1 1 0.94 1.20 0.50 0.80 0.71 0.95 1.20 0.87 1.19 2.79 16.21,
(0.68, 1.47) (0.98, 1.03) (0.98, 1.03) (0.79, 1.84) (0.22, 1.13) (0.55, 1.17) (0.44,1.13) (0.68, 1.33) (0.82, 1.74) (0.45, 1.68) (0.61, 2.33) (1.14, 6.81)∗ p = 0.18
China 1.74 1.04 0.95 3.96 1.79 0.20 0.67 1.24 2.11 1.54 2.39 0.36 71.46,
(0.94, 3.22) (1, 1.08) (0.78, 1.14) (1.76, 8.89)∗ (0.92, 3.49) (0.07, 0.52)∗ (0.29, 1.56) (0.67, 2.28) (0.95, 4.73) (0.70, 3.40) (0.38, 14.9) (0.05, 2.82) p < 0.01
India 2.44 1 0.78 0.75 1.23 0.63 0.21 0.63 0.80 0.94 1.60 3.30 93.94,
(1.57, 3.79)∗ (0.97, 1.04) (0.62, 0.97)∗ (0.30, 1.90) (0.79, 1.92) (0.37, 1.07) (0.08, 0.53)∗ (0.40, 0.97)∗ (0.36, 1.80) (0.12, 7.48) (0.89, 2.86) (1, 10.89) p < 0.01
Puerto Rico 0.54 0.96 1.01 1.60 2.00 0.25 0.06 5.05 0.80 1.60 1.64 1.27 50.74,
(0.28, 1.04) (0.93, 1) (0.79, 1.30) (0.87, 2.93) (0.73, 5.51) (0.13, 0.50)∗ (0.01, 0.41)∗ (1.24, 20.53)∗ (0.47, 1.35) (0.80, 3.22) (0.63, 4.23) (0.29, 5.57) p < 0.01
Pooled 1.29 1.03 0.93 1.43 1.84 0.69 0.69 0.92 1.05 1.18 1.65 0.03
(1.01, 1.51)∗ (0.99, 1.01) (0.87, 0.96)∗ (1.18, 1.72)∗ (1.49, 2.27)∗ (0.58, 0.82)∗ (0.56, 0.86)∗ (0.79, 1.01)∗ (0.86, 1.29) (0.91, 1.52) (1.34, 2.15) (0.02,0.04)
Higgins (I2) 76.2∗ 56.9 13.8∗ 45.5∗ 64.4∗ 69.9 59.30∗ 39.5 35 0 0 99.6
T2DM, type 2 diabetes mellitus. ∗indicates significance at < 0.05. Base group for comparison in sex is female, smoking status is ‘never smoked’, physical activity is ‘very often’, and hypertension,
T2DM and stroke are ‘no’. Figures in brackets are 95% confidence intervals. Coefficients for alcohol consumption in Peru and Venezuela were removed due to substantial instability (estimates
and associated confidence intervals <0.00001), stemming from low hazardous alcohol consumption rates (0.43% in Peru, 1.48% in Venezuela, while the average across other countries is 3.48%)
resulting in no cases of both hazardous alcohol consumption and COPD in these samples.
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Table 4
Associations of COPD with incident 10/66 dementia (competing risk proportional hazards regression), fully-controlled model coefficients
Site Unadjusted 95%L 95%U +Demographic 95%L 95%U †Demographic 95%L 95%U ‡Fully 95%L 95%U
SHR adjusted and health adjusted
SHR adjusted SHR SHR
Cuba 1.86 1.07 3.23∗ 2.16 1.25 3.74∗ 2.13 1.23 3.72∗ 1.95 1.07 3.54∗
Dominican Republic 0.80 0.41 1.56 0.83 0.42 1.64 0.81 0.41 1.60 0.86 0.43 1.69
Peru 0.30 0.04 2.22 0.37 0.05 2.78 0.40 0.05 2.99 0.40 0.05 2.94
Venezuela 1.22 0.66 2.25 0.83 0.42 1.65 0.88 0.43 1.79 1.31 0.50 3.40
Mexico 0.75 0.35 1.60 0.70 0.33 1.54 0.67 0.30 1.49 0.58 0.24 1.37
China 1.21 0.52 2.81 1.12 0.48 2.60 1.15 0.50 2.62 1.14 0.50 2.60
Puerto Rico 0.40 0.09 1.64 0.39 0.10 1.60 0.34 0.08 1.37 0.33 0.08 1.31
All Pooled 0.86 0.56 1.15 0.81 0.52 1.1 0.77 0.49 1.06 0.74 0.43 1.04
Higgins (I2) 14 8.6 17.5 7.24
SHR, sub-hazard ratio, +Accounting for the competing risk of dementia-free death, and adjusted for age, sex, education level. †Additionally
adjusting for smoking, physical activity, and hypertension. ‡Additionally adjusting for depression and hazardous alcohol consumption.
∗indicates significance at < 0.05.
Table 5
Associations of COPD with all cause mortality (cox regression), fully-controlled model coefficients
Site Unadjusted 95%L 95%U Demographic 95%L 95%U Demographic 95%L 95%U Fully 95%L 95%U
SHR adjusted and health adjusted
SHR adjusted SHR SHR
Cuba 1.19 0.81 1.75 1.18 0.8 1.74 1.06 0.71 1.58 1.07 0.73 1.58
Dominican Republic 1.77 1.3 2.39∗ 1.83 1.36 2.46∗ 1.7 1.26 2.29∗ 1.61 1.18 2.2∗
Peru 1.37 0.65 2.89 1.51 0.74 3.1 1.31 0.6 2.88 1.34 0.62 2.9
Venezuela 1.86 1.16 2.97∗ 1.42 0.88 2.28 1.31 0.76 2.26 1.04 0.48 2.26
Mexico 1.63 1.06 2.5∗ 1.52 0.99 2.33 1.44 0.93 2.24 1.35 0.86 2.12
China 1.69 1.09 2.63∗ 1.32 0.79 2.19 1.25 0.77 2.02 1.21 0.75 1.95
India 1.28 0.43 3.79 1.56 0.52 4.69 1.47 0.48 4.51 1.38 0.45 4.27
Puerto Rico 1.55 0.87 2.75 1.55 0.86 2.81 1.33 0.73 2.41 1.36 0.75 2.46
All Pooled 1.52 1.27 1.78∗ 1.51 1.28 1.78∗ 1.39 1.17 1.64∗ 1.32 1.14 1.58∗
Higgins (I2) 0 0 0 0
SHR, sub-hazard ratio, ∗indicates significance at < 0.05.
COPD and mortality325
I2 was noticeably low (<0.01 for all models), indi-326
cating that variation across studies was most likely327
due to heterogeneity rather than chance, thus pooled328
effects should be interpreted with caution. Pooled329
effects indicated that COPD was significantly associ-330
ated with premature death in all (unadjusted to fully331
adjusted) models, such that individuals with COPD332
had a 28% increased likelihood of premature death333
in the fully adjusted models. This association was334
significant for most countries in unadjusted mod-335
els, but only remained significant across models in336
the Dominican Republic (61% increased prevalence337
ratio).338
Sensitivity analysis339
Following the observation that COPD prevalence340
was lower than contemporary systematic reviews341
may suggest (e.g., [2]), analyses were re-run with342
a restricted age range (65–69) in order to align the343
current sample with the wider literature (Supple- 344
mentary Table 2). These models were unstable due 345
to the low prevalence of dementia at that age (134 346
cases across all sites). When all participants in this 347
age range across sites were combined into a sin- 348
gle analysis (n = 3,441), COPD did not significantly 349
predict dementia incidence even when it was sole 350
predictor (HR = 1.52, 95%CI [0.74,3.11], p = 0.25). 351
While the current competing risk proportional haz- 352
ards regression approach has established advantages 353
[33, 34], traditional Cox regression was also run 354
in order to explore COPD cause-specific hazards 355
(Table 5). Results were essentially the same, with 356
both approaches revealing a comparable pattern of 357
significance and magnitude of effects (Supplemen- 358
tary Table 3). 359
DISCUSSION 360
This study’s main findings were that COPD was not 361
consistently associated with risk of dementia across 362
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all LMIC investigated. However, COPD was associ-363
ated with premature death when all countries were364
pooled together. In addition, a robust association was365
detected between COPD and dementia incidence in366
Cuba and with premature death in the Dominican367
Republic.368
A paucity of data on the prevalence of COPD and369
its association with incident dementia and prema-370
ture death are available for LMIC. This is largely371
due to the high costs of conducting such investi-372
gations, which puts them out of reach of LMIC’s373
fragile economies, and to the methodological diffi-374
culties involved in collecting accurate data in these375
countries. The method used in the 10/66 study was376
specifically developed to overcome these barriers and377
further our understanding of dementia prevalence and378
risk factors in these communities.379
The present research showed that the prevalence380
of COPD in the regions studied ranged from 2.41%381
in China to 6.82% in the Dominican Republic. Our382
findings are therefore substantially lower than world-383
wide estimates reported in recent systematic reviews384
(∼10–12%) [2]. We can only speculate as to why this385
may be the case. A possible explanation is that mor-386
tality associated with COPD and its risk factors is387
higher in the regions studied and that the relatively388
old age of our sample (mean ∼75 years) reflects389
in part a survival effect that may have obscured its390
association with incident dementia. It is also likely391
that the measure of COPD used in this study, a392
single, indirect self-report question rather than the393
gold standard of spirometry, may not have identi-394
fied all cases. Available evidence suggests that the395
overwhelming majority of adults with COPD report396
chronic cough and sputum production, whereas 10%397
or less of those without COPD report these symptoms398
[22, 23]. Nevertheless, this measurement limitation399
most likely decreased the sensitivity of our anal-400
yses. It is also possible this misclassification bias401
may be non-differential (e.g., due to higher rates of402
pneumonia in dementia) and may have obscured true403
associations. Another possible source of misclassifi-404
cation was that, while analyses included a wide range405
of covariates associated with both COPD and demen-406
tia, information on region-specific factors, such as407
poorly ventilated indoor heat and cooking sources,408
and air pollution levels was unavailable.409
It is notable but not unexpected that smoking and410
physical activity were associated with COPD preva-411
lence at baseline, although these associations did not412
reach significance for all countries. Current smok-413
ing was positively associated with COPD in most414
countries except Mexico, and was associated with a 415
39% increased risk of having COPD. Past smoking 416
was also positively associated with COPD in most 417
countries except India, but was associated with a 418
slightly lower risk (34%). Relative to findings from a 419
recent systematic review reporting a 235% increased 420
risk in ex-smokers and 351% in current smokers, 421
the present estimates appear relatively low [35]. As 422
reported by Burney et al., this may be due to the fact 423
that the poorest people cannot afford to smoke and 424
therefore countries with the weakest economies are 425
more likely to have lower COPD rates [17]. In support 426
of this explanation, we computed the raw correlation 427
between the gross domestic product (GDP) of the 428
countries investigated in the present study at the time 429
of assessment and their prevalence of COPD (exclud- 430
ing China which was a major outlier with a high GDP 431
and very low COPD prevalence) and found a positive 432
association (r = 0.25), though this was not significant 433
(Fig. 2). 434
In contrast, physical activity was negatively asso- 435
ciated with COPD in all countries with those who 436
exercise fairly regularly or very regularly having a 437
64% and 54% lower risk of having COPD. How- 438
ever, these effects only reached significance in the 439
Dominican Republic, China, India, and Puerto Rico 440
and the direction of these effects are uncertain as 441
while exercise may be protective, it is also the case 442
that COPD limits physical activity. Other measures 443
associated with COPD at baseline in pooled analyses 444
included education (9% decreased risk), stroke (22% 445
increased risk), and depression (81% increased risk), 446
although the direction and strength of these effects 447
were not completely consistent across countries (e.g., 448
it is possible that COPD limited people’s capacity 449
to undertake physical activity, rather than lack of 450
physical activity increasing COPD risk). Contrary 451
to our expectation, COPD was not associated with 452
increased dementia risk in most countries except for 453
Cuba (95% increased likelihood). This is surprising 454
because in developed countries COPD, and partic- 455
ularly the reporting of chronic cough and sputum 456
production, are associated with poorer health out- 457
comes and increased dementia incidence [14, 15, 21]. 458
A plausible explanation for these findings is that those 459
affected by COPD in LMIC are less likely to live into 460
old age when dementia is more likely to manifest. 461
Indeed life expectancy at birth for the cohort con- 462
sidered here is approximately 69 years [36] and thus 463
it is more likely that a greater proportion of those 464
suffering from chronic diseases such as COPD may 465
have died before the start of the study. In contrast life 466
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Fig. 2. GDP and percent of sample with COPD. GDP figures sourced from Classora knowledge base, accessed 30/05/2018. Unadjusted line
of best fit indicates a positive, but non-significant association between GDP and COPD (r = 0.25, p = 0.59), where China is excluded due to
being an extreme outlier.
expectancy in Cuba, where the only significant asso-467
ciation was found between COPD and dementia, was468
81 years at the start of the study. Alternatively, this469
finding may simply reflect methodological issues that470
would be expected in a multi-center study (e.g., sam-471
pling variation), or be due to the limitations relating472
to the COPD measure and the dementia assessment473
procedure used.474
Similarly, COPD was positively associated with475
premature death in all countries but this effect only476
reached significance in the Dominican Republic477
(61% increased risk). However, unlike for demen-478
tia, when estimates were pooled across all countries,479
COPD was associated with a 32% increased risk of480
premature death. This is consistent with the expla-481
nation proposed above suggesting that the lack of482
associations found between COPD and dementia may483
be due to lower life expectancy. It is also in line with484
the literature showing a clear link between COPD485
and its underlying pathological processes and mor-486
tality [16]. This could be investigated in future work487
collecting data on COPD exposure duration. Simi-488
larly, a longer time period may provide more sensitive489
predictions of future Dementia diagnosis. In the cur-490
rent study it is possible individuals not diagnosed491
with dementia were actually in the lengthy pre-492
morbid phase [37]. Overall, these findings indicate493
that the link between COPD and dementia is currently494
somewhat different and weaker in LMIC than in 495
developed countries, and that this difference may be 496
due to premature death masking the development of 497
clinical dementia, at least in the older population 498
studied. The likely role of lower life expectancy in 499
LMIC in modulating these associations is important 500
to consider as recent world mortality reports have 501
indicated that life expectancy is rising quickly in 502
these countries. An implication for policy is therefore 503
that unless the disease burden associated with COPD 504
is addressed without delay, the future prevalence of 505
dementia will reach substantially higher levels as life 506
expectancy rises in LMIC. 507
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